BMO Capital Maintains Market Perform on Neurocrine Biosciences, Lowers Price Target to $150

Benzinga Newsdesk www.benzinga.com Negative 90.4%

Neg 90.4% Neu 0% Pos 0%

BMO Capital analyst Evan Seigerman maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Market Perform and lowers the price target from $164 to $150.